GlassScriptPhysician profile
Daniel Joseph Drew
NPI 1912060195
$6,194.50
in general payments reported to CMS, 2019-2025
29 companies · $1,113 in 2025
The $1,113 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $953 · 2020: $677 · 2021: $1,041 · 2022: $1,112 · 2023: $472 · 2024: $827 · 2025: $1,113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,412.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,745.68 | 2019-2025 | Evenity, Otezla, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $960.16 | 2019-2025 | Jardiance, Synjardy |
| Novartis Pharmaceuticals Corporation | $517.08 | 2021-2025 | |
| Lilly USA, LLC | $408.83 | 2019-2025 | Kisunla, Jardiance, Mounjaro |
| Glaxosmithkline, LLC. | $338.92 | 2019-2023 | Shingrix |
| Esperion Therapeutics, INC. | $276.21 | 2020-2025 | Nexletol |
| Novo Nordisk INC | $233.95 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $209.78 | 2019-2025 | |
| Inspire Medical Systems, INC. | $176.44 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $172.58 | 2020-2021 | |
| Eisai INC. | $140.46 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $134.56 | 2022 | |
| Boston Scientific Corporation | $129.45 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $121.83 | 2022 | |
| Gilead Sciences, INC. | $107.95 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $101.93 | 2023-2025 | Vraylar |
| Astellas Pharma US INC | $90.99 | 2020-2022 | |
| Amarin Pharma, INC. | $58.90 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.03 | 2019-2021 | |
| Allergan, INC. | $38.07 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $35.25 | 2024 | Dupixent |
| Sumitomo Pharma America, INC. | $29.72 | 2023-2025 | Gemtesa |
| Sunovion Pharmaceuticals INC. | $26.94 | 2022 | |
| Chiesi USA, INC. | $16.39 | 2023 | Kengreal, Cleviprex |
| Sanofi Pasteur INC. | $14.16 | 2023 | |
| Janssen Pharmaceuticals, INC | $14.07 | 2019 | |
| Nestle Healthcare Nutrition INC. | $13.65 | 2021 | |
| Painteq LLC | $13.36 | 2024 | Painteq |
| Antares Pharma, INC. | $11.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Drew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.